Behavioral effects of ketamine and toxic interactions with psychostimulants

BMC Neuroscience

Volumn 7, Issue , 2006, Pages

  Hayase, Tamaki ^a   Yamamoto, Yoshiko ^b   Yamamoto, Keiichi ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yamamoto Research Institute of Legal Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; KETAMINE; METHAMPHETAMINE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG FATALITY; DRUG MECHANISM; DRUG OVERDOSE; FORCED SWIMMING TEST; LETHALITY; LOCOMOTION; MAZE TEST; MORTALITY; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; SEIZURE; SINGLE DRUG DOSE;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; INJECTIONS, INTRAPERITONEAL; KETAMINE; LETHAL DOSE 50; LOCOMOTION; MALE; MAZE LEARNING; METHAMPHETAMINE; MICE; MICE, INBRED ICR; MODELS, ANIMAL; MOTOR ACTIVITY; RECEPTORS, N-METHYL-D-ASPARTATE; SEIZURES; SUBSTANCE-RELATED DISORDERS; SWIMMING;

EID: 33744802362     PISSN: 14712202     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-7-25     Document Type: Article

References (58)

1. Dundee JW, Knox JW, Black GW, Moore J, Pandit SK, Bovill J, Clarke RS, Love SH, Elliott J, Coppel DL: Ketamine as an induction agent in anaesthetics. Lancet 1970, 1:1370-1371.
2. Wright M: Pharmacologic effects of ketamine and its use in veterinary medicine. J Am Vet Med Assoc 1982, 180:1462-1471.
3. Hahn N, Eisen RJ, Eisen L, Lane RS: Ketamine-medetomidine anesthesia with atipamezole reversal: practical anesthesia for rodents under field conditions. Lab Anim 2005, 34:48-51.
4. Nonaka A, Suzuki S, Masamune T, Imamura M, Abe F: Anesthetic management by total intravenous anesthesia with propofol, pentazocine and ketamine. Masui 2005, 54:133-137.
5. Fitzpatrick M: Special K. Lancet 2003, 361:620.
6. Gable RS: Acute toxic effects of club drugs. J Psychoactive Drugs 2004, 36:303-313.
7. Pandit SK, Kothary SP, Kumar SM: Low dose intravenous infusion technique with ketamine. Amnesic, analgesic and sedative effects in human volunteers. Anaesthesia 1980, 35:669-675.
8. Hansen G, Jensen SB, Chandresh L, Hilden T: The psychotropic effect of ketamine. J Psychoactive Drugs 1988, 20:419-425.
9. Jansen KL: Non-medical use of ketamine. BMJ 1993, 306:601-602.
10. Smith KM: Drugs used in acquaintance rape. J Am Pharm Assoc 1999, 39:519-525.
11. Babar E, Ozgunen T, Melik E, Polat S, Akman H: Effects of ketamine on different types of anxiety/fear and related memory in rats with lesions of the median raphe nucleus. Eur J Pharmacol 2001, 431:315-320.
12. Yilmaz A, Schulz D, Aksoy A, Canbeyli R: Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002, 71:341-344.
13. Vanderwende C, Spoerlein MT, Lapollo J: Cocaine potentiates ketamine-induced loss of the righting reflex and sleeping time in mice. Role of catecholamines. J Pharmacol Exp Ther 1982, 222:122-125.
14. Uchihashi Y, Kuribara H, Tadokoro S: Assessment of the ambulation-increasing effect of ketamine by coadministration with central-acting drugs in mice. Jpn J Pharmacol 1992, 60:25-31.
15. Gill JR, Stajic M: Ketamine in non-hospital and hospital deaths in New York City. J Forensic Sci 2000, 45:655-658.
16. Riley SC, James C, Gregory D, Dingle H, Cadger M: Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction 2001, 96:1035-1047.
17. Thomson AM, West DC, Lodge D: An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature 1985, 313:479-481.
18. Irifune M, Shimizu T, Nomoto M, Fukuda T: Ketamine-induced anesthesia involves the N-methyl-D-aspartate receptor-channel complex in mice. Brain Res 1992, 596:1-9.
19. Irifune M, Shimizu T, Nomoto M: Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice. Pharmacol Biochem Behav 1991, 40:399-407.
20. Van der Meersch-Mougeot V, da Rocha M Jr, Monier C, Diquet B, Puech AJ, Thiebot MH: Benzodiazepines reverse the anti-immobility effect of antidepressants in the forced swimming test in mice. Neuropharmacology 1993, 32:439-446.
21. Cancela LM, Basso AM, Martijena ID, Capriles NR, Molina VA: A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study. Brain Res 2001, 909:179-186.
22. Paine TA, Jackman SL, Olmstead MC: Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol 2002, 13:511-523.
23. Hayase T, Yamamoto Y, Yamamoto K, Muso E, Shiota K, Hayashi T: Similar effects of cocaine and immobilization stress on the levels of heat-shock proteins and stress-activated protein kinases in the rat hippocampus, and on swimming behaviors: the contribution of dopamine and benzodiazepine receptors. Behav Pharmacol 2003, 14:551-562.
24. Bell RF: Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain 1999, 83:101-103.
25. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA: Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 1999, 843:171-183.
26. Yamakura T, Mori H, Masaki H, Shimoji K, Mishina M: Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuroreport 1993, 4:687-690.
27. Berman FW, Murray TF: Characterization of [3H]MK-801 binding to N-methyl-D-aspartate receptors in cultured rat cerebellar granule neurons and involvement in glutamate-mediated toxicity. J Biochem Toxicol 1996, 11:217-226.
28. Uzbay IT, Wallis CJ, Lal H, Forster MJ: Effects of NMDA receptor blockers on cocaine-stimulated locomotor activity in mice. Behav Brain Res 2000, 108:57-61.
29. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, Wang YM, Caron MG: Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 2000, 3:465-471.
30. Bubar MJ, McMahon LR, De Deurwaerdere P, Spampinato U, Cunningham KA: Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens. Neuropharmacology 2003, 44:342-353.
31. Smith DJ, Bouchal RL, deSanctis CA, Monroe PJ, Amedro JB, Perrotti JM, Crisp T: Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology 1987, 26:1253-1260.
32. Pal HR, Berry N, Kumar R, Ray R: Ketamine dependence. Anaesth Intensive Care 2002, 30:382-384.
33. Chutuape MA, de Wit H: Relationship between subjective effects and drug preferences: ethanol and diazepam. Drug Alcohol Depend 1994, 34:243-251.
34. Garfield JM, Garfield FB, Stone JG, Hopkins D, Johns LA: A comparison of psychologic responses to ketamine and thiopental - nitrous oxide - halothane anesthesia. Anesthesiology 1972, 36:329-338.
35. Moretti RJ, Hassan SZ, Goodman LI, Meltzer HY: Comparison of ketamine and thiopental in healthy volunteers: effects on mental status, mood, and personality. Anesth Analg 1984, 63:1087-1096.
36. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G: Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:687-700.
37. Derlet RW, Albertson TE, Rice P: Antagonism of cocaine, amphetamine, and methamphetamine toxicity. Pharmacol Biochem Behav 1990, 36:745-749.
38. Sofia RD, Gordon R, Gels M, Diamantis W: Comparative effects of felbamate and other compounds on N-methyl-D-aspartic acid-induced convulsions and lethality in mice. Pharmacol Res 1994, 29:139-144.
39. Witkin JM, Gasior M, Heifets B, Tortella FC: Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine. J Pharmacol Exp Ther 1999, 289:703-711.
40. Bachus SE, Gale K: Muscimol microinfused into the nigrotegmental target area blocks selected components of behavior elicited by amphetamine or cocaine. Naunyn Schmiedebergs Arch Pharmacol 1986, 333:143-148.
41. Velíšková J, Velíšek L, Mareš P, Rokyta R: Ketamine suppresses both bicuculline- and picrotoxin-induced generalized tonic-clonic seizures during ontogenesis. Pharmacol Biochem Behav 1990, 37:667-674.
42. Ye JH, Liu PL, Wu WH, McArdle JJ: Cocaine depresses GABAA current of hippocampal neurons. Brain Res 1997, 770:169-175.
43. Grant KA, Knisely JS, Tabakoff B, Barrett JE, Balster RL: Ethanol-like discriminative stimulus effects of non-competitive n-methyl-d-aspartate antagonists. Behav Pharmacol 1991, 2:87-95.
44. Sanger DJ: Substitution by NMDA antagonists and other drugs in rats trained to discriminate ethanol. Behav Pharmacol 1993, 4:523-528.
45. Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS: Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 1998, 55:354-360.
46. Boyer CS, Petersen DR: Enzymatic basis for the transesterification of cocaine in the presence of ethanol: evidence for the participation of microsomal carboxylesterases. J Pharmacol Exp Ther 1992, 260:939-946.
47. Hayase T, Yamamoto Y, Yamamoto K: Stress-related behavioral alterations accompanying cocaine toxicity: the effects of mixed opioid drugs. Nihon Arukoru Yakubutsu Igakkai Zasshi 2000, 35:402-414.
48. Hayase T, Yamamoto Y, Yamamoto K: Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. Behav Pharmacol 2005, 16:395-404.
49. Rogerio R, Takahashi RN: Anxiogenic properties of cocaine in the rat evaluated with the elevated plus-maze. Pharmacol Biochem Behav 1992, 43:631-633.
50. Hayase T, Yamamoto Y, Yamamoto K, Abiru H, Nishitani Y, Fukui Y: Effects of ethanol and/or cardiovascular drugs on cocaine- and methamphetamine-induced fatal toxicities in mice. Nihon Arukoru Yakubutsu Igakkai Zasshi 1999, 34:475-490.
51. Szumlinski KK, Haskew RE, Balogun MY, Maisonneuve IM, Glick SD: Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their antiaddictive properties. Pharmacol Biochem Behav 2001, 69:485-491.
52. Hayase T, Yamamoto Y, Yamamoto K: Brain excitatory amino acid transporters (EAATs) and treatment of methamphetamine toxicity. Nihon Arukoru Yakubutsu Igakkai Zasshi 2003, 38:498-511.
53. Porsolt RD, Le Pichon M, Jalfre M: Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
54. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
55. Hayase T, Yamamoto Y, Yamamoto K: Toxic cocaine- and convulsant-induced modification of forced swimming behaviors and their interaction with ethanol: comparison with immobilization stress. BMC Pharmacol 2002, 2:19.
56. Prior H, Schwegler H, Marashi V, Sachser N: Exploration, emotionality, and hippocampal mossy fibers in nonaggressive AB/Gat and congenic highly aggressive mice. Hippocampus 2004, 14:135-140.
57. Przewlocka B, Lason W, Machelska H, Przewlocki R: The effects of cocaine-induced seizures on the proenkephalin mRNA level in the mouse hippocampus: a possible involvement of the nitric oxide pathway. Neurosci Lett 1994, 168:81-84.
58. Alves SH, Pinheiro G, Motta V, Landeira-Fernandez J, Cruz AP: Anxiogenic effects in the rat elevated plus-maze of 5-HT(2C) agonists into ventral but not dorsal hippocampus. Behav Pharmacol 2004, 15:37-43.